Freenome (FRNM) said Tuesday it has launched the SimpleScreen Lung cancer test for adults aged 50 to 80 with a smoking history of over 20 packs a year who are currently not participating in any guideline-recommended screening.
The test can be ordered independently or alongside the US Food and Drug Administration-approved SimpleScreen colorectal cancer test when average-risk patients are also eligible for blood-based colorectal cancer screening, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments